Conor Medsystems Faces IP Hurdles To Reach DES Market, Plans $70 Mil. IPO

Conor Medsystems will build a direct sales force for U.S. marketing of its CoStar drug-eluting stent (DES) using proceeds from an initial public offering of up to $70 mil. in common stock